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ABSTRACT
Stroke and traumatic brain injury are devastating disorders that often lead to
permanent neurologic deficits, with few available treatment options once injury has
occurred. In previous work, Anti-Nogo-A immunotherapy has been shown to neutralize
the neurite inhibitory protein, Nogo-A, and to promote neuronal plasticity and improve
functional recovery after stroke in the rat. Furthermore, other reports have demonstrated
that environmental enrichment improves functional recovery in rodents following stroke.
Our previous work demonstrated that anti-Nogo-A immunotherapy also helps promote
cortical plasticity in the rodent. In the current project, we examined two methods to
promote recovery after brain injury, a stroke model (MCAO) and a traumatic brain injury
model (TBI). This work also studied whether environmental enrichment (enriched
housing and focused activity) paired with Anti-Nogo-A immunotherapy shortened the
recovery time and increased the neuronal plasticity of aged rats who had received focal
ischemic stroke, produced by middle cerebral artery occlusion. Additional work
examined whether Anti-Nogo-A immunotherapy alone could lead to a shorter recovery
time and increased plasticity in animals that sustained traumatic brain injury. The skilled
forelimb reaching task and the skilled ladder rung walking test were used to assess
sensorimotor recovery. Dendritic plasticity was studied using the Golgi-Cox staining
method. Our results show that dendritic plasticity was increased in the middle cerebral
artery occlusion animals but decreased in the traumatic brain injury animals compared to
xii

age-specific naïve animals. However, there was no significant difference in performance
on behavioral tasks in the rats receiving Anti-Nogo-A or control antibody in both the
MCAO and TBI experiments.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
Literature Review
The Global Problem of Stroke:
Worldwide, stroke is a devastating neurological condition that often leads to
permanent disability or death in adults. The World Health Association estimated in 1999
that stroke led to 5.54 million deaths world-wide, mostly occurring in less developed
countries (The World Health Report 1998, 1998; The World Health Report 2000, 2000).
The end point of stroke is, of course, not always death but may be a crippling disability
that leads to an enormous socioeconomic burden. The approximate costs for each stroke
patient range from $59,800-230,000 in their lifetime after stroke (The World Health
Report 1998, 1998; The World Health Report 2000, 2000). Stroke mortality trends may
have decreased in industrialized nations recently, although this is controversial (Gillum,
1997). Nonetheless, stroke is a deadly killer and disabler that we must work to silence.
Stroke:
There are two types of stroke: ischemic stroke and hemorrhagic stroke. Ischemic
stroke occurs when blood flow to an area of the brain is reduced. When this occurs, the
1
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affected area of the brain is damaged and can no longer function properly. Ischemic
strokes account for 67.3-80.5% of all strokes (Feigin, Lawes, Bennett, & Anderson,
2003). Some of the known major risk factors of stroke are: high blood pressure, smoking,
diabetes, high cholesterol, heart disease and arterial fibrillation. People with known
histories of heart disease and diabetes, especially men, African Americans and people
over the age of 55 are at most risk for stroke (Feigin et al., 2003; Gillum, 1997; Gillum &
Sempos, 1997; Murray & Lopez, 1997; Sarti, Rastenyte, Cepaitis, & Tuomilehto, 2000).
Traumatic Brain Injury:
Traumatic brain injury (TBI) is an acquired injury to the brain that occurs because
of sudden trauma. Symptoms in this type of injury range from mild to severe according to
amount of brain damage. TBI patients may also experience trauma to the rest of the body
as well because of the nature of the accident. Extensive trauma proves to be more
difficult to treat because of the likely involvement of various other organ systems in the
body. Not unlike ischemic stroke, TBI is also very difficult to study and treat in the aged
population because of the multifaceted effects it has on the nervous system. It can lead to
disability as well as death, especially in the aged population.
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Global Problem of Traumatic Brain Injury:
The National Institutes of Health (NIH) identified adults older than 75 years of
age to be in the high risk group for acquiring traumatic brain injury (Traumatic Brain
Injury: Hope Through Research, 2002). The Centers for Disease Control and Prevention
(CDC) conducted a survey across nine states in the United States looking at the
hospitalization rate for elderly patients with traumatic brain injury. In this work, the
hospitalization rate was 105 patients per 100,000 for those 65-74 years of age, while the
rate was 287 per 100,000 for those patients over 75 years of age ("Rates of
Hospitalization Related to Traumatic Brain Injury-- Nine States, 2003," 2007). Another
survey conducted by the CDC determined that falls were the highest contributor to TBI in
the elderly population and the next was motor vehicle accidents ("Rates of
Hospitalization Related to Traumatic Brain Injury-- Nine States, 2003," 2006). It was
found that 79% of TBI victims over the age of 65 suffered from co morbid health
condition(s) (Cuadrado, Egido, Gonzalez-Gutierrez, & Varela-De-Seijas, 1999). These
data suggest that TBI is indeed a deadly condition within the aged population and great
strides are needed to help advance recovery in these patients.
Age and Brain Injury:
As the elderly population is rapidly growing, disorders associated with age such
as stroke and traumatic brain injury are on the rise (Popa-Wagner, Carmichael, Kokaia,
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Kessler, & Walker, 2007; Uomoto, 2008). Accordingly, clinical research is being
developed to further understand the basic mechanisms involved in stroke as well as
preventive measures and therapies to ease the burden of the disease on the aged
population. Studying stroke and TBI in the aged population is especially challenging
because these adults often suffer from other diseases as well. Moreover, old age and the
related changes that occur in the brain contribute to the poor recovery of the brain after
stroke and TBI (Hukkelhoven et al., 2003; Rosen, Dinapoli, Nagamine, & Crocco, 2005).
The difficulty understanding the age-related mechanisms underlying stroke and TBI leads
to challenges in designing effective therapies to treat elderly patients.
Treatment Options—Stroke:
Due to the challenging nature of stroke, treatment options are quite limited. The
current accepted treatment used to reduce the severity of stroke is tissue plasminogen
activator (Brouns & De Deyn, 2009; del Zoppo, 2000; Cheatwood, Emerick, & Kartje,
2008). This treatment is only effective in a short-time window of three hours after the
stroke has occurred. Numerous clinical drug trials (over 150) have studied a variety of
other treatments for stroke, involving ion channel blockers, anti-inflammatory drugs,
glutamate antagonists, and free-radical scavengers (Cheng, Al-Khoury, & Zivin, 2004;
Faden & Stoica, 2007; Ginsberg, 2007; Savitz, 2007; Savitz & Fisher, 2007; Young, Ali,
Duretete, & Vivien, 2007). These clinical trials have all proven to be highly
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disappointing. Because of the failed attempts to develop effective neuroprotective agents,
patient care after stroke is generally geared toward various rehabilitation techniques that
will aid the patient to live close to normal life as possible.
Treatment Options: Traumatic Brain Injury:
Treatment options for TBI are also scarce, with no clearly proven treatments
available, and this reflects the very short time window where treatments could work to
alleviate the injury and promote greater recovery. Little can be done to reverse the injury
in TBI patients while medical personnel work to stabilize the patient from further
damage. Sometimes, brain surgery is needed to treat contusions or hematomas
(Traumatic Brain Injury: Hope Through Research, 2002). Rehabilitation currently is the
most promising treatment for TBI. The NIH recommends that patients should be fitted
with individualized programs to help rehabilitate them according to their strengths and
weaknesses (Traumatic Brain Injury: Hope Through Research, 2002). Accordingly,
scientists are working to develop treatments to solve the complex problem of
understanding and treating traumatic brain injury.
Nervous System and Injury:
Because the nervous system is extremely complex, the effects and progression of
brain injury are multifaceted. After injury, degenerative processes in the peripheral and
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central nervous systems are similar in some ways, but inherent promoters of growth and
environmental stimuli differ between the two systems (Fenrich, 2003; Liu, Cafferty,
Budel, & Strittmatter, 2006). As a striking difference, the central nervous system (CNS)
has a very limited capacity for recovery after injury compared to the peripheral nervous
system, which is more regenerative and allows for more recovery.
In 1927, Santiago Ramon y Cajal noted that the CNS had a non-permissive
nature, meaning various factors in the brain do not allow for new growth to happen after
injury (Liu et al., 2006). In landmark studies, Aguayo and Richardson used a peripheral
nerve graft to create a permissive environment that promoted axonal regeneration of
damaged CNS neurons (Aguayo, David, & Bray, 1981; Richardson, McGuinness, &
Aguayo, 1982). Later experiments discovered inhibitors in the myelin that collapsed
growth cones and prevented neurite outgrowth in vitro (C. Bandtlow, Zachleder, &
Schwab, 1990; Savio & Schwab, 1989) and in vivo (Schnell & Schwab, 1990). Other in
vivo work found that regenerating neurons ceased activity when they encountered
astrogliosis areas (Davies, Goucher, Doller, & Silver, 1999). Such experiments showed
that inhibitory molecules are a good target for therapies to create a more permissive CNS
environment and thus more recovery after injury.
Plasticity and regeneration are structural processes that may occur in the CNS and
PNS to lead to recovery after injury. Regeneration in this context refers to regrowth of the
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damaged axons after damage, and, even though this progression may occur, it does not
mean full functional recovery. Plasticity, on the other hand, typically refers to the
compensatory measures, such as remodeling, of the undamaged neurons in response to an
injury (Kartje & Schwab, 2006).
Regeneration mainly occurs in the PNS, but may occur, although rarely, in the
CNS. In order for regeneration to happen, the damaged neuron must somehow be rescued
and restored. The process of Wallerian degeneration separates the damaged axon from
the neuron, as well as primes the neuron for the possibility of a successful axonal
regeneration (Fenrich, 2003). In the initial stages of axonal injury, calcium influx triggers
axonal proteases that then help break down the axolemma and axoplasm (E. B. George,
Glass, & Griffin, 1995; Schlaepfer & Bunge, 1973; Stoll, Griffin, Li, & Trapp, 1989;
Stoll, Jander, & Myers, 2002). Next, proliferating Schwann cells use various mediators
such as regeneration associated genes (RAGs), growth associated protein-43 (GAP-43),
neurotropic factors, Schwann cell proliferative factor, neuregulin and erb receptors (Boyd
& Gordon, 2003; Cohan, 1992; Fu & Gordon, 1997; Hall, 1999; LeBlanc & Poduslo,
1990) in its efforts to form bands of Bünger from the myelin debris (Fenrich, 2003). The
bands of Bünger serve as a guide for axon regeneration from the proximal distal stump
(Hirata & Kawabuchi, 2002; Liu et al., 2006; Stoll et al., 1989; Stoll et al., 2002).
Macrophages are essential in the degeneration process, since they phagocytize the
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damaged myelin (Bruck, 1997; Hirata & Kawabuchi, 2002). In the CNS and the PNS,
axotomized neurons undergo chromatolysis (morphological changes occurring at the cell
soma) to prime the area for regeneration to occur (Kreutzberg, 1996). These neurons also
express proteins that aid the interaction between the Schwann cells and neurons to ensure
regrowth.
CNS axons undergo the degeneration process described above but at a slower
pace due to the limited phagocytic ability of resident microglia (R. George & Griffin,
1994; Rapalino et al., 1998). The presence of growth inhibitors such as Nogo-A decreases
growth after injury (C. E. Bandtlow & Schwab, 2000; R. George & Griffin, 1994;
Rapalino et al., 1998; Stoll & Muller, 1999). The oligodendrocytes do not dedifferentiate
into growth supportive cells like the Schwann cells and therefore are not able to help aid
in new growth (Fenrich, 2003). The regrowth of injured axons seen in the PNS is rarely
seen in the CNS.
Obstacles to Regrowth in Central Nervous System:
There are many factors that provide obstacles in the path of neurite growth. Some
molecular components that act as barriers to new growth include: chondroitin sulphate
proteoglycans (CSPG), tenascin, semaphorins-3A (Davies et al., 1999; Letourneau,
Condic, & Snow, 1994; Pasterkamp, Ruitenberg, & Verhaagen, 1999), neurocan
versican, phosphacan and NG2 (Liu et al., 2006). More specifically, Nogo-A, myelin-
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associated glycoprotein (MAG) and oligodendrocyte glycoprotein (OMgp) are inhibitors
located in the myelin of axons in the central nervous system (Schwab 2004). Neurite
growth is hindered by this very potent growth inhibitor—Nogo-A. This inhibitor leads to
growth cone collapse in neurites and therefore prevents regrowth in the central nervous
system (C. E. Bandtlow & Schwab, 2000). Axonal regeneration was much improved in
experiments with mice that do not express Nogo-A compared to wild-type controls (Kim,
Li, GrandPre, Qiu, & Strittmatter, 2003; Simonen et al., 2003). The non-permissive
nature of Nogo-A is also found in cell migration of fibroblasts as well (Buchli & Schwab,
2005; Caroni & Schwab, 1988).
Nogo
The nogo gene was initially discovered when investigators fractionated adult CNS
myelin and found membrane- associated proteins, identified as NI-35/250, according to
molecular weights determined by SDS-PAGE (Caroni & Schwab, 1988). Later, a short
peptide sequence was characterized as a homolog of NI-35/250, named bovine bNI220
(Spillmann, Bandtlow, Lottspeich, Keller, & Schwab, 1998) and which possessed potent
inhibitory characteristics. Further research determined that application of monoclonal
antibody IN-1, specific to the amino region of Nogo-A, after spinal cord injury in rats
promoted the regeneration of corticospinal tract axons (Bregman et al., 1995; Brosamle,
Huber, Fiedler, Skerra, & Schwab, 2000; Schnell & Schwab, 1990). It was further
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determined that IN-1 could neutralize the amino-terminal domain of Nogo-A (Fiedler,
Horn, Bandtlow, Schwab, & Skerra, 2002) and thus prevent growth cone collapse in the
CNS myelin (C. E. Bandtlow, Schmidt, Hassinger, Schwab, & Kater, 1993).
The nogo/RTN-4 gene produces three isoforms: Nogo-A, Nogo-B and Nogo-C.
Nogo-A, found in oligodendrocytes, myelin, and neuronal populations, is a high
molecular weight (200 kDa) protein that is involved in inhibiting neurite growth (Chen et
al., 2000; GrandPre, Nakamura, Vartanian, & Strittmatter, 2000; Prinjha et al., 2000).
Nogo-B (55 kDa), a splice form of Nogo-A, is expressed ubiquitously in many tissues
and functions in vascular remodeling (Acevedo et al., 2004), apoptosis (Li et al., 2001),
and modulation of vascular smooth muscles and migration of endothelial cells (Acevedo
et al., 2004; Oertle & Schwab, 2003). Nogo-C (25 kDa) comes from the nogo gene using
an alternate promoter. The function of Nogo-C is not very well known, but it has been
found to delay peripheral nerve regeneration in experiments in vivo (Kim, Bonilla, Qiu, &
Strittmatter, 2003). Nogo-C is expressed in differentiated muscle fibers, as well as
Purkinje cells in the brain (Acevedo et al., 2004; Dupuis et al., 2002; Huber, Weinmann,
Brosamle, Oertle, & Schwab, 2002; Hunt, Coffin, Prinjha, Campbell, & Anderson, 2003;
Li et al., 2001; Tozaki, Kawasaki, Takagi, & Hirata, 2002).
All three Nogo isoforms are reticulon proteins, specifically in the reticulon-4
(RTN-4) family. A fairly short amino (N)-terminal sequence is common to many

11

reticulon proteins (Schwab, 2004). The reticulon proteins are evolutionarily very old.
Nogo-A‟s long N-terminal sequence developed later in evolution as a result of a fusion of
old homology domains and new sequences, which thus led to a novel function (Oertle &
Schwab, 2003; Oertle et al., 2003). The Nogo proteins, like most reticulon proteins, are
located in the endoplasmic reticulum (ER) and are highly involved in ER processes, such
as developing the shape of the ER (Caroni & Schwab, 1988; Chen et al., 2000; Dodd et
al., 2005; GrandPre et al., 2000; Prinjha et al., 2000; Voeltz, Prinz, Shibata, Rist, &
Rapoport, 2006). In reticulon proteins and more specifically Nogo-A, -B, and -C, there
are 2 large hydrophobic domains near the C-terminus (Chen et al., 2000; GrandPre et al.,
2000). Between the two domains lies the 66 amino acid loop, which the Nogo Receptor
(NgR) subunit binds to (Fournier, GrandPre, & Strittmatter, 2001). This domain must be
displayed on the extracellular face of the oligodendrocyte in order for the receptor on the
surface of neurons or fibroblasts to be activated (Dodd et al., 2005).
Nogo Receptor and Downstream Effects:
NgR is a glycosyl phosphatidyl inositol (GPI) linked leucine-rich repeat
glycoprotein (Barton et al., 2003; Fournier et al., 2001; He et al., 2003). There are
currently three known isoforms of this receptor: NgR1, NgR2, and NgR3. NgR1 and 2
are involved in the growth inhibitory processes of the CNS (Fry, Ho, & David, 2007).
NgR1 binds selectively to the OMgp, MAG, and the Nogo-66 portion of Nogo-A, while

12

NgR2 only binds to MAG (Filbin, 2003; Venkatesh et al., 2005). NgR is a glycoprotein
expressed in many neuronal populations. Due to expression of the Nogo-A protein on the
cell surface and lack of an intracellular domain, the co-receptors p75 (Wang, Kim,
Sivasankaran, Segal, & He, 2002; Wong et al., 2002), TROY (Park et al., 2005; Shao et
al., 2005), and LINGO-1 (Mi et al., 2004) are required in order for intracellular signaling
(Fournier et al., 2001).
TROY and p75, members of the tumor necrosis factor family, aid in signal
transduction across the cell membrane, while LINGO-1 is an adaptor protein
(Gonzenbach & Schwab, 2008). When the receptor complex is stimulated at the surface,
a small intracellular GTPase, RhoA becomes activated and leads to actin
depolymerization and growth cone collapse (Zhang, Zhang, Zhang, & Qin, 2008).
Growth cone collapse occurs through the actions of proteins such as collapsin-1 and
semaphoring III (D). These proteins collapse the lamellipodial and filopodial structures of
growth cones of neurons and therefore inhibit axonal outgrowth. Another set of proteins,
rho, and rac1 are modulators of this process (Jin & Strittmatter, 1997).
Recent evidence has suggested that the myelin inhibitory growth molecules on
different populations of neurons may use different receptor systems (Giger et al., 2008).
Paired immunoglobulin-like receptor B (PirB) is a high affinity receptor for MAG, OMgp
and Nogo-A. This receptor can bind to the Nogo-66 region and thus lead to neurite

13

outgrowth (Atwal et al., 2008). In in vivo and in vitro experiments where NgR was
genetically blocked and PirB was blocked by antibodies Atwal et al., (2008) showed that
these two receptors may collaborate in the demanding process of growth cone collapse.
Nogo-A also has an Amino-Nogo region, which does not bind to NgR, and also
leads to neurite outgrowth (Oertle et al., 2003). This region, independently from NgR, has
been shown to prevent fibroblast activity and axonal regrowth in vitro (Fournier et al.,
2001; Oertle et al., 2003). IN-1 has been shown to bind specifically to the amino region
of Nogo-A and neutralize the protein (Fiedler et al., 2002). This region can also bind to
integrins and block their downstream signal transduction (Hu & Strittmatter, 2008).
Blockade of Nogo:
Blockade of the Nogo-A receptor/protein complex and downstream intracellular
signaling may lead to better recovery from injury in the CNS. One such method that has
been developed is raising antibodies against Nogo-A, that then block its ability to inhibit
neurite growth. This has been heavily studied in animal models of cortical injury, such as
traumatic brain injury (TBI) and stroke. The inhibitory effect of IN-1 on Nogo-A is
supported by in vitro assays (Caroni & Schwab, 1988) as well as spinal cord injury
studies in vivo (Bregman et al., 1995; Schnell & Schwab, 1990; Thallmair et al., 1998;
Z'Graggen, Metz, Kartje, Thallmair, & Schwab, 1998).
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Nogo-A Immunotherapy:
Ischemic stroke in the sensorimotor cortex leads to loss of the ability for rats to
perform functional tasks such as the skilled forelimb reaching task (Cheatwood et al.,
2008; Papadopoulos et al., 2002). This is a very precise task that requires the animal to
learn fine digit control and controlled arm movements. The corticospinal tract which
arises from layer V pyramidal cells in the sensorimotor cortex is involved in this task,
and, when it is damaged, the animal loses its ability to successfully complete the task
(Whishaw, 2000). Anti-Nogo-A therapy has been used in experiments to try to
rehabilitate rats undergoing middle cerebral artery occlusion (MCAO), an animal model
of stroke. This therapy has been used to promote forelimb functional recovery after
stroke. Investigations have discovered that the contralesional cortex plays an important
role in sensorimotor recovery after injury (Cramer et al., 1997; Cuadrado et al., 1999).
Intracerebral administration of the IN-1 antibody leads to improved performance at the
skilled forelimb reaching task (Papadopoulos et al., 2002). Further investigations showed
that the antibody therapy could be administered a week after MCAO and still promote
functional recovery (Seymour et al., 2005). This is an important observation, because an
effective treatment one week after ischemic insult extends the previous very short (3
hour) treatment period to a larger window of opportunity to be able to treat stroke.
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Anti-Nogo-A immunotherapy has also been found to improve forelimb motor
function when administered by the intrathecal route one week after MCAO (Tsai et al.,
2007). A more clinically relevant model involving the neutralization of Nogo-A after
MCAO in the aged rat found that the use of an anti-Nogo-A antibody (7B12) aided in
functional recovery in the aged animal, although significant functional recovery was not
seen until 9 weeks after stroke (Markus et al., 2005).
Anti-Nogo-A therapy promotes forelimb function in rats after a cerebral cortical
lesion (Emerick & Kartje, 2004). This recovery correlated with the observed remodeling
of motor cortical pathways. After administration of anti-Nogo-A mAb, new fibers have
been seen to project from the contralesional brain regions to regions associated with the
injured hemisphere (Cheatwood et al., 2008). The presence of IN-1 mAb in the lesioned
dorsal corticospinal tract has led to regenerative sprouting in the damaged axons
(Schwab, 2004). Animals treated with the IN-1 mAb a week after strokes were found to
have significantly higher corticorubral fiber ratios as compared with their control
counterparts (Seymour et al., 2005). The effective benefits of anti-Nogo-A treatments on
cortical pathways and cortical plasticity after cortical aspiration lesions have been shown
in multiple studies. Remodeling occurs in the corticorubral and corticopontine fibers in
the adult brain after IN-1 treatment in rats receiving unilateral cortical lesions (Wenk,
Thallmair, Kartje, & Schwab, 1999). Functional recovery in animals treated with IN-1
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after unilateral pyramidal tract lesions was associated with new growth of corticopontine
and corticorubral fibers which crossed the midline (Z'Graggen et al., 1998). IN-1
treatment led to structural plasticity after lesions in corticospinal tracts of animals,
specifically new growth in intact and lesioned axons in the cervical spinal cord, red
nucleus and pons (Thallmair et al., 1998).
Experiments using Nogo-A/B deficient aged mice found that functional outcome
was impaired after cortical injury (Marklund et al., 2009). This suggests that Nogo-A
may play a role in the development of the brain and the genetic deletion of Nogo-A may
exacerbate injury. Marklund‟s group also reported an improvement in cognitive function
after treatment with anti-Nogo-A therapy after brain injury (Marklund et al., 2009).
Further immunotherapy treatment involved non-human primates subjected to a
unilateral cervical lesion to the spinal cord. Using the modified Brinkman board task (a
motor function task) the monkeys that received anti-Nogo-A therapy displayed
significantly better performance than their control Ab counterparts. An increase in
corticospinal axonal sprouting was seen in the area of the lesion in the animals receiving
anti-Nogo-A therapy. Therefore, the enhanced sprouting after injury played a role in
functional recovery after stroke (Freund et al., 2009).
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Dendritic Plasticity:
Noticeable shortening of the basal dendrites of prelimbic pyramidal neurons in
layers V/VI have been seen in animals after traumatic brain injury (Hoskison et al.,
2009). Recovery after cortical damage may be due to the dendritic plasticity in the
dendrites of neurons (Biernaskie, Chernenko, & Corbett, 2004; Jones & Schallert, 1994).
Treatment of rats with IN-1 after stroke resulted in an increase in dendritic plasticity,
specifically in layer V pyramidal neurons of the forelimb motor cortex of the
contralesional cortex (Papadopoulos et al., 2006). This increase in dendritic and axonal
plasticity may represent a compensatory measure by the brain in its attempt to regain
functional use of the limbs.
Environmental Enrichment:
Environmental enrichment has long been studied in the laboratory for its effects
on various diseases and to better understand its mechanisms. More specifically, it has
been found that rodents living in environmental enrichment conditions experience
considerable changes in the brain at the cellular and molecular levels (Bennett,
Rosenzweig, Diamond, Morimoto, & Hebert, 1974; Rosenzweig & Bennett, 1996).
Environmental enrichment allows animals to be housed in conditions that allow for social
interactions as well as sensory and motor stimulation (Mora, Segovia, & del Arco, 2007;
Rosenzweig & Bennett, 1996; van Praag, Kempermann, & Gage, 2000). There are
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several categories of enrichment for laboratory rodents: structure and substrate,
manipulanda, novel foods, social contact, and other types of enrichment which stimulate
senses other than touch and taste (Hutchinson, Avery, & Vandewoude, 2005).
Environmental Enrichment and Brain Plasticity:
Plasticity of the brain can be impacted by enriched environmental conditions, as
shown in numerous studies. Although, there is no published standard of ideal
environmental enrichment conditions, a general idea of what is appropriate has
developed. Three experimental housing conditions are mentioned consistently across the
literature—standard conditions, environmental conditions, and impoverished conditions.
Standard conditions refer to typical laboratory rodent environment, in which 2-6 rats are
housed per cage, without any play objects. The enriched environment housing has larger
groups of animals, as well as larger cages filled with objects for stimulation and play.
Lastly, the impoverished condition is when animals are singly housed in small cages
without any objects (Will, Galani, Kelche, & Rosenzweig, 2004).
In 1874, Charles Darwin noted that wild rabbits had increased brain sizes, compared to
their domestic counterparts (Mohammed et al., 2002). In the 1960s, the first controlled
experiments that subjected animals to environmental enrichment were conducted
(Diamond, 2001). In the wild-type rodent, enriched environment was shown to enhance
dendritic arborization, alter spine morphology, increase neurogenesis in the hippocampus,
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increase neurotrophin levels, induces changes in NMDA and AMPA expression, as well
as enhance learning and memory. In rodents with ischemic stroke, environmental
enrichment enhances functional motor recovery, attenuates learning/memory deficits,
increases dendritic arborization, increases levels of neurotropic factors, normalizes
deficits seen in cell proliferation in subventricular zone and in glucocorticoid and
mineralcorticoid receptors, as well as others (Nithianantharajah & Hannan, 2006). It also
has been found that aged animals also reap the beneficial effects from the enriched
environment. Environmental enrichment was found to lead to better functional motor
recovery in the skilled forelimb reaching task in rats after cerebral ischemia (Knieling,
Metz, Antonow-Schlorke, & Witte, 2009). Taking all these observations together, I
hypothesize that placing aged animals in enriched environment after ischemic stroke, and
giving them Nogo-A immunotherapy will lead to better functional recovery on the
behavioral, cellular and molecular levels.

CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS

Hypothesis: Anti-Nogo-A immunotherapy facilitates environmental enrichment mediated
functional recovery and neuronal plasticity in aged rats receiving focal ischemic stroke.
Specific Aim 1: Determine if Anti-Nogo-A immunotherapy added to environmental
enrichment will improve performance in the skilled forelimb reaching task or ladder rung
walking test in aged (20 months) Fisher 344 rats after stroke.
Specific Aim 2: Determine if Anti-Nogo-A immunotherapy added to environmental
enrichment will increase dendritic plasticity in the contra-lesional forelimb area of the
motor cortex in aged (20 months) Fisher 344 rats after stroke.
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CHAPTER 3
EXPERIMENTAL DESIGN AND METHODS

A.

Animals
a.

Control Animals
Two aged (24 months) naïve Fisher 344 rats were designated as normal

aged controls in this study. They were trained on the skilled forelimb reaching
task and the skilled ladder rung walking test. They did not receive any surgeries
or any other treatments. They were sacrificed after 4 weeks and their brains were
processed by the Golgi-Cox method to determine dendritic morphology.
b.

MCAO Experiments
Ten aged male Fisher 344 rats at 18 months upon arrival were used in this

study. They received ad libitum water and standard rat food and were maintained
on a 12 hour light-dark cycle. Because of the fragile nature and mortality of the
aged rats, we completed the experiment with two rats in the control group
receiving control antibody and four rats receiving anti-Nogo-A antibody (11c7) in
the experimental group. Four animals (23 months of age; two control antibody
and two 11c7 antibody animals) were perfused for Golgi analysis. Figure 1 shows
the experimental design for the MCAO experiments.
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c.

TBI Experiments
The TBI experiments were designed and conducted by Ian Vaagenes.

Twenty aged (18 months) male Fisher 344 rats were used in this set of
experiments. The animals received ad libitum water and standard rat food and
were maintained on a 12 hour light-dark cycle. Because of high mortality, only
four animals in the control IgG antibody group and five animals in the anti-NogoA antibody group survived. Six animals (three in the control antibody group and
three in the 11c7 antibody group) were sacrificed at 24 months of age for Golgi
analysis. Figure 2 shows the experimental design for the TBI experiments.
B.

Housing
a.

MCAO Experiments
In the training period before the animals received the stroke surgery and

treatments, animals were housed in standard lab cages, two per cage.
After the stroke surgery and surgeries for the antibody pumps, all
surviving animals were placed in large plexiglass cages (81.5 cm X 61 cm X 45
cm) outfitted with various objects for exploration (Figure 3). These objects were
distributed in the cage on a weekly rotation (Week A and Week B). Week A
objects were: Bundle of Twig Nibblers, Nature Ball and Bag „o‟ Chews. Week B
objects were: Nylabone, Build „n‟ Bites, and a Bag of Chew Toys. Toys were
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placed in novel areas every week to encourage exploration. Also due to the fragile
nature of the animals and weight loss seen in the animals, fruit loops, and mashed
rat food were introduced to the cage as well. These food items were only supplied
when the colony seemed sickly. We provided the food to promote stable weights
in the animals, but the food could also be seen as a form of environmental
enrichment because it added a novel stimulus to their surroundings.
b.

TBI Experiments
TBI animals were housed in standard lab cages, two per cage throughout

the duration of the study.
C.

Behavioral Tasks
a.

Skilled Forelimb Reaching Task
Upon arrival, all animals were trained everyday on this task, which

measures fine digit motor control and coordination of the forelimbs. Animals
were trained in a clear plexiglass box (30 X 36 X 30 cm) with a rectangular
window (1.5 X 3 cm) open at the base of the floor (Markus et al., 2005;
Papadopoulos et al., 2002; Seymour et al., 2005; Tsai et al., 2007) (Figure 4A).
To promote forelimb reaching, small sucrose pellets (45 mg; Bilaney Consultants,
NJ) were placed on a platform outside of the window of the box.
When the initial training period began, food restriction was initiated and
the animal‟s weight was not allowed to drop below 95% of their baseline body
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weight. Food restriction was lessened as the task was learned. Water was freely
available.
Animals were trained in this task for 6-7 weeks before receiving MCAO
or TBI. Animals were required to reach a baseline (of 15/20 pellets in less than
five minutes) to be considered for this study. Animals were tested in the task five
days after MCAO or TBI surgeries, as well as five days after the antibody pump
was inserted and again five days after it was removed. After all surgeries, animals
were tested everyday (Monday-Friday) for the duration of the study. The TBI
animals were tested for 13 weeks following surgery, while the MCAO animals
were tested for 9 weeks after surgery. Animals were video taped once a week for
analysis.
b.

Skilled Ladder Rung Walking Test
Animals were familiarized on the ladder rung test, twice a week, two

weeks before MCAO or TBI. This test consists of an animal walking across a
narrow 1 meter long Plexiglass frame with bars placed every 2.5 cm as described
in previous work (Emerick & Kartje, 2004; Metz & Whishaw, 2002)(Figure 4B).
The animals were encouraged to walk across by placing a tray of sucrose pellets
on the opposite end of the walk-way. The animals tended to walk toward the tray
of sucrose pellets. This activity is not forced.
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This test is designed to measure foot slips and this test evaluates sensory
and motor function. The test sessions included three runs on the apparatuses and
were video-taped for analysis. Before the MCAO or TBI surgeries, animals were
video-taped in a baseline test session. After the MCAO or TBI surgeries, animals
were video-taped once a week for the duration of the experiments. The TBI
animals were tested for 13 weeks after injury and the MCAO animals were tested
for 9 weeks.
D.

Middle Cerebral Artery Occlusion (MCAO)
All animals underwent a middle cerebral artery occlusion (MCAO) at the
culmination of the behavioral training (Markus et al., 2005; Papadopoulos et al.,
2002; Papadopoulos et al., 2006; Seymour et al., 2005; Tsai et al., 2007).
Isoflurane (inhalant 5% with oxygen) was used to initially anesthetize the animals
for the procedure. For the duration of the procedure, animals received Isoflurane
(3% with oxygen) to maintain the anesthetized state. First, the animal‟s head and
neck were shaved and cleaned with iodine. The animal then was placed in a
stereotaxic instrument, and a 2 centimeter vertical incision was made on the head,
between the eye and the ear. The temporalis muscle was pulled back to expose the
skull. A burr hole to the skull, specifically the parietal bone of the skull, exposed
the parietal cortex. The middle cerebral artery (MCA) was visualized where it
transverses the rhinal sulcus. The MCA was permanently ligated with a 10-0
monofilament suture. The MCA was also transected above the suture with

26

microscissors. The occlusion of the MCA was done on the side opposite to the
preferred forelimb (i.e. right hand; left MCAO). The temporalis muscle was
sutured with a 4-0 absorbable suture, and the skin was closed with 4-0
monofilament nylon sutures.
After the MCAO, the animal was placed in the supine position. A midline
longitudinal incision was made on the animal‟s neck to expose the common
carotid artery on both sides (CCA). The CCA were freed carefully from the vagus
nerve and surrounding tissues. The CCA ipsilateral to the side of the MCAO was
permanently ligated with a 4-0 silk suture. The contralateral CCA was occluded
for thirty minutes by the use of an aneurysm clip in some animals. The temporary
occlusion was eliminated from the procedure after mortality in several animals in
the surgeries to allow a better survival rate in the animals. After the CCA‟s were
occluded and ligated, the incision was closed with 4-0 monofilament sutures.
Animals were placed on a warm water circulating heating pad covered
with a towel. They also received a subcutaneous injection of buprenorophine (0.1
mg/kg) upon awakening for pain management and then put back into their home
cages. The animals received injections of buprenorophine (0.1 mg/kg) twice a day
for three days after the surgery for proper pain management. The sutures to the
skin were removed 14 days after surgery.
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E.

Traumatic Brain Injury (TBI)
All animals in this study underwent a traumatic brain injury (TBI) at the
culmination of the behavioral training (Miller et al., 2001). Isoflurane (inhalant
5% with oxygen) was initially used to anesthetize the animals for the procedure.
For the duration of the procedure, animals received Isoflurane (3% with oxygen)
to maintain the anesthetized state. First, the animal‟s head and neck were shaved
and cleaned with iodine. Then the animal was placed in a stereotaxic instrument.
A midline incision to the head exposed the skull.
A craniotomy of 4 mm was performed at position 0.5 mm anterior and 4
mm lateral to the bregma. This is estimated to be directly over the forelimb
sensorimotor cortex. A controlled cortical impact injury device was used to
deliver the traumatic brain injury. The device consists of a small bore, double
acting, pneumatic piston cylinder with a 40 mm stroke mounted on a stereotaxic
micro-manipulator. The accurate determination of the piston coordinates is
performed by referencing a sharp concentric tip on bregma and moving it to the
previously mentioned coordinates. The concentric tip is then replaced by the
impactor tip (3 mm diameter). The pneumatic piston cylinder is angled 22.0°
away from vertical so that the flat impactor tip is perpendicular to the surface of
the brain. The impactor tip strikes the brain at 1.7 m/sec to a depth of 1.7 mm
below the cortical surface for 250 msec. After impact, the scalp was closed with a
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4-0 monofilament nylon suture. Post-operative procedures were similar to those
used after MCAO surgery.
F.

Rehabilitation Methods
a.

Nogo-A Immunotherapy
One week after MCAO and TBI surgeries Alzet mini-osmotic pumps,

(Durect Corporation, Cupertino, CA) were implanted in the animals to promote
recovery in the injured brain as described in previous work (Gillani et al., 2009;
Markus et al., 2005; Papadopoulos et al., 2002; Papadopoulos et al., 2006;
Papadopoulos et al., 2009; Ramic et al., 2006; Seymour et al., 2005; Tsai et al.,
2007). Animals were anesthetized for the implantation procedure with isoflurane,
as described above. The head and back of the animal were shaven, cleaned with
iodine, and then the animal was placed in the stereotaxic instrument.
A small incision was made in the midscapular area where a subcutaneous
pocket was surgically created with blunt scissors. This pocket housed the osmotic
pump. The osmotic pump was placed in the pocket, and the catheter was led
subcutaneously to the cranial site for cannula placement. A mid-line scalp incision
was made to expose the skull, and one burr hole was made on the same side of the
skull (ipsilateral to the MCAO) to receive the cannula. The cannula was placed at
coordinates: lateral 1.3 mm; posterior 0.8; and dorsoventral 3.8, relative to the
bregma cranial landmark. The external portion of the cannula was secured to the
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skull using Cryanoacrylate Gel (recommended by Alzet). The scalp was then
closed over the cannula apparatus with 4-0 mnofilament nylon sutures. The
incision made to house the pump in the back was sutured with 4-0 mnofilament
nylon sutures. After surgery, the incisions were closed up and animals received
post-operative care as described above.
These pumps provided an intracerebroventricular (icv) administration of
either purified anti-Nogo-A Ab 11c7 (monoclonal mouse IgG), or a purified
control mouse IgG Ab. The pumps infused 5 mg of the Ab (2.5 mg/ml) at the rate
of 15 µg/hour to the affected area for two weeks (Markus et al., 2005).
After two weeks of this antibody therapy, the pumps were removed. The
rats were anesthetized and prepared for surgery as described above. Two incisions
were made just large enough to remove the pump, cannula, and all tubing. After
the items were removed, the incisions were closed up with 4-0 monofilament
sutures. Post-operative procedures are similar to those described above.
b.

Focused Activity Sessions
After the completion of all surgical procedures, only the MCAO animals

participated the in focused activity sessions, which were geared toward forcing
the animals to use and rehabilitate the affected limbs. The focused activity
consists of a playground with three apparatuses that encouraged animals to use
their forelimbs. The three apparatuses were located in a 5‟X5‟ enclosed space
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equipped with a 45 degree inclined ladder (200 cm X 5 cm), vertical rope (100
cm), and a vertical cylindrical grid (100 cm X 10 cm; 1-cm^2) (Papadopoulos et
al., 2009). Figure five shows an illustration of our focused activity playgrounds.
These sessions were held twice a day for four weeks and then only held
once a day for the duration of the study. Sessions that were held twice daily were
done in the morning and afternoon. Sessions held once a day were done in the
afternoon. All sessions were done after behavioral testing (skilled forelimb
reaching task and skilled ladder rung walking test) to ensure maximum
performance on the behavioral tests. At first, animals were doing twenty minute
sessions but were subsequently reduced to ten minutes per session, as the animals
appeared to tire with 20 minute sessions. Every week, one minute was added to
the session time, to promote endurance and rehabilitation. Animals were rotated
on the three apparatuses at one minute intervals for the time allotted for the
session. Animals were not allowed to be idle in the activities but were encouraged
to keep exploring and moving around.
G.

Golgi Analysis
Four MCAO animals and six TBI were sacrificed for Golgi analysis. All
animals were 21-24 months of age when sacrificed. The animals were overdosed
with sodium pentobarbital (100 mg/kg, i.P.) and transcardially perfused with
0.9% heparinized saline. The whole brains were dissected out and placed in
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Golgi-Cox solution (Glaser and van der Loos, 1981). The brains were left in the
solution for 14 days and then in 30% sucrose for 1-2 days. The brains were cut on
a vibratome into 200 μm coronal sections and placed on frosted, pre-cleaned
microscope slides.
Brains were reacted using a procedure described by Gibb and Kolb (1998).
Slides with brain sections were placed in a slide rack and then placed in a tray
containing ammonium hydroxide solution for 30 minutes. They were washed in
distilled water for a minute and then transferred to a tray with Kodak Fix
(Eastman Kodak Company) for 30 minutes. After a one minute wash in distilled
water, the slides were placed in 50%, 70%, and 95% ethanol for 1 minute each.
Then the slides were placed in two different 100% ethanol trays for two five
minute sessions. After the ethanol washes, the slides are then transferred into a
tray that contains equal parts of 100% ethanol, chloroform (≥ 99%) and Citrisolv
(Fisherbrand) for 10 minutes. Then, the slides are transferred into a tray
containing Citrisolv for 15 minutes. This is done twice, using a clean tray filled
with Citrisolv each time. In the process, several things are important to ensure a
good reaction. One is that slide racks should be blotted with Kimwipes (Kimtech)
before each transfer. Also, before each session, the slide rack is dipped up and
down quickly several times in the solution and then placed in the tray for the time
allotted for that session. After the reaction, the bottoms of the slides are blotted
with Kimwipes and the tops are blotted with Bibulous Paper (Scientific Products),
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and then the slides are coverslipped using Permount (Fischer Scientific). Slides
must be stored on a flat surface in a dark space for 3-4 days to allow for the tissue
to be mounted properly.
The slides were then viewed with a Leica DM 4000 B light microscope
outfitted with a CX9000 camera (MicroBrightfield Inc.). Pyramidal neurons were
selected from cortical layer V in the forelimb area (S1FL) of the brain, in
accordance to measurements seen in the Rat Brain Atlas (Paxinos and Watson; 4th
Edition, 1998). According to the atlas, area S1FL is found in the range of 1.20
mm to -2.12 mm from the bregma. Other criteria for selecting a neuron for
analysis included: a tear drop cell body, strong apical dendrite and good
branching seen apically and basally. Eight neurons per brain were traced and
analyzed using the Neurolucidia (Microbrightfield Inc.) program. The neurons
were selected on the side opposite of the lesion in both the MCAO and TBI brains
to determine dendritic plasticity that may have occurred. The data from this
technique was further analyzed statistically and graphically. In our analysis we
looked at the apical and basal dendritic lengths and the number of branch
segments. In the normal aged control group, both hemispheres were examined,
and therefore 16 neurons per brain were traced.
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H.

Lesion Analysis
Lesion analysis was done on the brains that were processed for the Golgi
technique. The stroke volume was quantitatively analyzed using the Scion Image
1.63 Alias software. The software allowed us to trace lesions and calculate the
surface area of the lesion. Stroke size was calculated by subtracting the area of the
lesioned size from the non-lesioned side, dividing it by the non-lesioned side and
multiplying it by 100 (Papadopoulos et al., 2002).

I.

Statistics
In analyzing the behavioral tasks (skilled forelimb reaching task and
skilled ladder rung walking test), we used GraphPad Prism 4 to perform a
repeated measures ANOVA for comparison of control Ab/MCAO & control
Ab/TBI, 11c7 Ab/MCAO & 11c7 Ab/TBI, 11c7 Ab/MCAO & control
Ab/MCAO, and 11c7 Ab/MCAO & control Ab/MCAO. For analysis of the
Golgi-Cox results, we used SigmaStat to perform a T-Test on the following
groups: 11c7 Ab/MCAO & 11c7 Ab/TBI, control Ab/MCAO & control Ab/TBI,
11c7 Ab/TBI & control Ab TBI, and 11c7 Ab/MCAO & control Ab/MCAO. For
the lesion analysis, we used GraphPad to perform a T-Test on the following
groups: 11c7 Ab/TBI and control Ab/TBI. P values less than 0.05 were
considered significant.
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Group

Initial
N

MCAO

12

TBI

N for
Behavioral
Studies

20

N for Golgi
Analysis
2
4

Control
Ab
11c7 Ab

2
2

4
5

Control
Ab
11c7 Ab

3
3

Table 1: Animal Groups: Shows the group sizes for the various studies in our
experimental design. (N is group size).
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Figure 1: Time-line for MCAO Experiments. Abbreviations are as follows: FL
(forelimb reaching task), BW (skilled ladder rung walking test), Ab Rx (antibody
treatment), EE (environmental enrichment). Animals were 23 months of age at the
time of perfusion.
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Figure 2: Time-line for TBI experiments: (as designed by Ian Vaagenes).
Abbreviations are as follows: FL (forelimb reaching task), BW (skilled ladder
rung walking test), Ab Rx (antibody treatment). Animals were 23 months of age
at the time of perfusion.
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Figure 3: Enriched housing: in which the MCAO rats lived in after surgeries. Toys,
cat scratcher, igloos and food-bowls provided as form of enrichment.
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(A)

(B)
Figure 4: Behavioral Tasks: (A) F344 Rat, 5 days post-MCAO attempting the
Skilled Forelimb Reaching Task. (B) Same rat, 5 days post-MCAO attempting the
Skilled Ladder Rung Walking Test. The foot-slip seen in the image denotes a
deficit in the animal after MCAO.
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Figure 5: Focused activity playground: in which the MCAO rats did daily
rehabilitation exercises after surgeries. Apparatuses, in an enclosed space, on the
playground include: ladders, wire mesh grid and vertical rope ladder.

CHAPTER 4
RESULTS

A.

Animals/Housing
This study proved to be very challenging because of the fragile nature of
the Fisher 344 rats. In the first couple of MCAO surgeries, the animals died due to
surgical complications. Therefore, the MCAO procedure was amended to promote
survival in the remaining animals. Instead of occluding and ligating both of the
CCA, and prolonging the surgery, we decided to permanently ligate the CCA
ipsilateral to the lesioned side. Of the ten animals in the MCAO group, only 6
survived stroke surgeries. In view of our increasing awareness of the fragility of
these animals, we constantly checked their weights and looked for other signs of
declining health. Of the 20 animals in the TBI group, 9 animals survived the TBI
surgeries.

B.

Lesion Analysis
Analysis of the stroke lesions of the MCAO/11c7 Ab showed a mean size
of 14.15%. The mean size of the stroke lesions in the MCAO/control Ab animals
was 7.31%. In the TBI/11c7 animals, the mean size of the cortical lesion was
3.42%. The TBI/Control Ab animals showed a mean size of the cortical lesion to
40
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be 6.61%. Figure 13 shows the stroke volume of all groups. The size of the lesion
did not differ between the TBI/11c7 Ab and TBI/control Ab groups (p= 0.3985,
T-Test).
C.

Behavioral Tasks
a.

Skilled Forelimb Reaching Task
This task compared four groups of animals: MCAO/11c7 Ab (N=4),

MCAO/Control Ab (N= 2), TBI/11c7 Ab (N=4) and TBI/Control Ab (N=4). All
animals experienced a significant deficit after the MCAO and TBI surgeries
(Figure 6).
As seen in figure 6, the TBI animals appeared to recover better over time
in this task as compared to the MCAO animals, but no statistical significance was
observed. In the TBI group, the animals receiving 11c7 Ab tended toward better
performance over time, as compared to the control Ab animals. Also, the TBI
animal that received 11c7 Ab nearly recovered back to baseline levels.
The MCAO group of animals seemed to perform about the same over time
regardless of what treatment they received. It is important to note that none of the
stroke animals recovered back to their baseline level at the time point of 7 weeks
after MCAO surgery. This was also true for the TBI animals at the time point of
10 weeks after TBI surgery. Both groups of animals did, however, recover from a
profound deficit of in reaching performance (0 pellets out of 20), to a decent score
(11-15 pellets out of 20 in TBI; 7-8 pellets out of 20 in MCAO). In comparing the
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11c7 Ab/MCAO animals to the control Ab/MCAO animals, there is almost a
significant difference between the groups (P= 0.055).
b.

Skilled Ladder Rung Walking Test
In this test, we compared four group: the 11c7 antibody/MCAO group, the

control antibody/MCAO group, the 11c7 antibody/TBI group and the control
antibody/TBI group (Figure 7).
At baseline, the MCAO animals had an average of about 0.6 foot-slips per
10 steps. Five days after the MCAO, this increased to about 0.8 slips per 10 steps
in the control antibody animal group and about 1.3 slips per ten steps in the 11c7
antibody group. Preceding the stroke surgery, there was no statistically significant
difference between the two groups of animals. A decrease in the number of slips
over time was observed after MCAO, but this did not return to baseline levels.
Also, the behavior of these animals was notable. After stroke, the animals had a
very crouched posture and walked across the bars very gently as if they were
afraid to slip. They seemed to put more weight on the non-affected side, as well as
on the hind paws. This led to more slips in the hind paws. Over time, the animals
stopped this compensatory posture and developed a more normal posture for
crossing the bars.
In the TBI group, the baseline average was about 2 foot-slips per 10 steps
in both groups. After the TBI surgery, this rate rose to an average of about 5 footslips per 10 steps in both groups. After the TBI surgery, there was little difference
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seen in the performance of the 11c7 Ab group as compared to the control Ab
group over time. A general decrease of foot-slips was observed in both groups
over time that returns fairly close to baseline levels. Statistics were not done at
this time due to low numbers in groups as well as incomplete data.
D.

Rehabilitation
c.

Immunotherapy
In the MCAO experiments, a total of six animals received immunotherapy.

They all survived the surgeries, except for one who died two days after minipump removal. This animal did receive the 11c7 antibody. Of the remaining five
animals, 3 animals received the 11c7 antibody and 2 animals received the control
antibody.
In the TBI experiments, a total of nine animals received antibody
treatment. Four animals received the control antibody, while five animals received
the control antibody treatment. Eleven animals in the original group of 20 died
before the pump surgeries.
d.

Environmental Enrichment
Animals were placed in environmental enrichment conditions (focused

activity and enriched housing) after they received immunotherapy treatments.
Initially, they received 20 minute sessions on the focused activity playground,
twice a day. This was following the behavioral tasks. It was quickly noted, after a
week of rehabilitation, that 40 minutes per day of rehabilitation appeared too
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stressful for the animals. The animals were falling off the different apparatuses
and appeared exhausted. The following week, the sessions were reduced to 10
minutes each, for a total of 20 minutes per day. One minute was added to the total
time each week to push for greater functional recovery. (i.e. week two was 11
minutes, week three was increased to 12 minutes). The animals performed two
sessions a day for four weeks and then one session a day for the remaining five
weeks. At first the animals were inactive on the playgrounds, but over time they
learned how to interact with the equipment and started exploring more. They also
developed better climbing skills on the rope and vertical wire mesh. These
changes could be attributed to functional recovery of the limbs. There was no
apparent difference between the two groups as far as their activity on the
playground. When animals appeared sick, their activity was greatly hampered.
As for the housing conditions, the animals spent most of their time in a
plastic igloo, sleeping. When they were first placed in the enriched housing, they
did not explore as much. Over time, the animals explored more and sought out the
objects placed in their cages. The toys that the animals liked best were: twigs, bag
„o‟ chews, build „n‟ bites, and the bag of wooden chew toys. Affinity was
measured through daily observation of which toys the animals moved around, and
by the condition of the toys when the week was over. The best liked toys were
consumed or gnawed on. There are four different levels in the housing that the
animal could explore. Generally, the animals stayed on the first two levels. Where
the animals had been was also noted by whether animals had moved the toys
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around in that location, as well as general observations made throughout the week
of their whereabouts. The animals were more active at night, which fits with their
nocturnal nature.
E. Golgi Analysis
Six TBI brains, two naïve brains and four MCAO brains were analyzed
via the Golgi-Cox method. Layer V pyramidal neurons in the forelimb area of the
sensorimotor cortex were analyzed. The basal dendrites and the apical dendrites
were analyzed for the following: individual length of branches, individual branch
segments, total lengths, and total branch segments. The MCAO animals show
increased numbers in the total number of branch segments, while the TBI animals
show decreased numbers, compared to the normal aged animals. However, only a
few comparisons between groups were significant. In comparing the 11c7
Ab/MCAO group to the 11c7 Ab/TBI group, we get a P value of 0.017 in the
apical branches (Figure 8) and a P value of 0.018 in the basal branches (Figure 9).
This shows that there is a significant difference in the branch segments of
dendrites in animals with two different types of lesions, and the same type of
immunotherapy. Figure 10 shows the total dendritic length for the apical dendrites
across groups. Figure 11 shows the total dendritic length for the basal dendrites
across groups. Both the MCAO animals and TBI animals show decreased
numbers in the total dendritic length as compared to the normal aged animals.
Statistically, the 11c7 Ab/MCAO group compared to the 11c7 Ab/TBI group was
statistically significant for both the apical (P value = 0.045) and basal dendrites (P
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value = 0.058). Anti-Nogo-A immunotherapy seems to have a different effect on
the dendritic length of neurons in brains affected by different lesions. Figure 12
shows representative tracings for the following groups: 11c7 Ab/MCAO, 11c7
Ab/TBI, control Ab/MCAO, control Ab/TBI, and normal adult control.
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Figure 6: Forelimb reaching scores over time. The data shows the number of
successful reaches out of twenty pellets. Brain injury refers to either TBI or
MCAO. Error bars denote standard error of the mean. Mixed ANOVA was done
to determine statistics but no significance was found at this time. The following
abbreviations used are: Ab Rx (antibody treatment), Ab (antibody), TBI
(traumatic brain injury), MCAO (middle cerebral artery occlusion).
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Figure 7: Skilled Ladder Rung Walking Test: Data measures the number of slips
out of every ten steps that the animal takes across the ladder. Brain injury refers to
either TBI or MCAO. Statistics were not done at this time. Abbreviations are as
follows: Ab (antibody), Ab Rx (antibody treatment), TBI (traumatic brain injury),
MCAO (middle cerebral artery occlusion).
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Figure 8: Golgi-Cox analysis of Total Branch Segments in the Apical Dendrites of
the animals. Brain injury designates either MCAO or TBI. Error bars denote the
standard error of the mean. *P<0.05 for 11c7 treated MCAO and TBI groups (TTest P values reported).
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Figure 9: Golgi-Cox analysis of Total Branch Segments in the Basal Dendrites of
the animals. Brain injury refers to either MCAO or TBI. Error bars denote the
standard error of the mean. *P<0.05 for 11c7 treated MCAO and TBI groups (TTest P values reported).
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]

Figure 10: Golgi-Cox analysis of total Dendritic Lengths of the Apical Dendric
trees of the animals. Brain injury refers to either MCAO or TBI. Error bars
denote the standard error of the mean. *P<0.05 for 11c7 treated MCAO and TBI
groups (T-Test P values reported).
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Figure 11: Golgi-Cox analysis of total Dendritic Lengths of the Basal Dendritic
Trees of the animals. Brain injury refers to either TBI or MCAO. Error bars
denote the standard error of the mean. *P<0.05 for 11c7 treated MCAO and TBI
groups (T-Test P values reported).
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Figure 12: Box-plots comparing Golgi staining of MCAO group (n= 4 animals;
n= 32 neurons) to TBI group (n=6 animals; n= 48 neurons). The neurons in
the MCAO group have significantly improved dendritic plasticity in both the
apical and basal dendrites, as well as in both the branch segments and the
dendritic length.
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Figure 13: Representative Golgi-Cox stained layer V pyramidal neurons from the
FL area in the motor cortex. Drawings are from Neurolucidia program. All
neurons were traced at 10x magnification under a light microscope. (A)
Representative neuron from the normal aged animal. (N = 32 neurons) (B)
Representative neuron from MCAO/11c7 animal. (N= 32 neurons) (C)
Representative neuron from a MCAO/control animal. (N= 16 neurons) (D)
Representative neuron from TBI/11c7 animal. (N= 24 neurons) (E)
Representative neuron from a TBI/control animal. (N= 24 neurons)
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14: Lesion analysis of the TBI and MCAO brains after injury. Shows the lesion
size, which is represented as a percent of the intact hemisphere. There was no
significant difference between the two TBI groups (p= 0.3985, T-Test). Error bars
denote the standard error of the mean. Statistics was not done in the MCAO
groups because of low N (11c7 Ab had N=1 and Control Ab had N=2).

CHAPTER 5

DISCUSSION
Aged Brain and Injury
Perhaps the most significant problem in studying cortical injury in the aged brain
is how to effectively stimulate plasticity in order to promote functional recovery. The
complexity of the aged brain is multiplied when considering that the elderly often also
suffer from a vast amount of interconnected co-morbidities associated with aging.
Sometimes, it is impossible to separate aged-related diseases such as adult-onset diabetes
and stroke because they are so intertwined. A key question is how to manipulate the
injured aged brain in such a way to allow for functional recovery.
The aged population is known to recover poorly from brain injury (Lindner, Gribkoff,
Donlan, & Jones, 2003; Rosen et al., 2005) and also suffers from greater disabilities after
stroke as compared to younger populations (Kelly-Hayes et al., 2003). A variety of
therapies have been suggested for the two types of cortical injury discussed in this
paper—ischemic stroke and TBI. The lack of available clinical drugs and therapies
approved and on the market shows just how complex brain injury is and that we have a
long way to go to understand how to treat the complex processes in brain injury.

56

57

Age and Stroke
The risk of acquiring ischemic stroke increases with age (Lloyd-Jones et al., 2009).
The brain undergoes many changes with increasing age that make it more susceptible to
stroke. Studies in the aged rat induced with ischemic stroke have revealed factors such as
increased cardiac arrhythmias and myocardial insults (Rosen et al., 2005), lack of
autonomic influences on cerebral blood flow (Hachinski, Oppenheimer, Wilson,
Guiraudon, & Cechetto, 1992), increase in proliferating and apoptotic cells (PopaWagner et al., 2007), and excessive release of glutamate leading to nerve damage
(Rothman, 1984). It is important to take into account all the various factors that are
involved in stroke in the aged when studying the course of the disease and treatment.
Age and Traumatic Brain Injury:
Aged individuals recover very poorly after TBI and are likely to suffer from increased
rates of TBI due to falls ("Rates of Hospitalization Related to Traumatic Brain Injury-Nine States, 2003," 2006). Perhaps the biggest obstacle to recovery in patients with
traumatic brain injury is that axonal regeneration is inhibited in the CNS. This inhibition
is prevalent across all age groups but is especially present in the aged brain. The elderly
brain is not as plastic as it is at a younger age and thus causes recovery from TBI to be
slow and often incomplete (Marklund et al., 2009).
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Brain Injury Treatments:
Treatment options for ischemic stroke are quite scarce and most treatment is directed
toward general rehabilitation after injury. Many clinical trials and experiments have
targeted various factors and processes involved in cerebrovascular disease and have
generally failed for several reasons. Treatment for TBI also is very hard to treat clinically
and most treatment is geared toward alleviating the symptoms. As the world-wide elderly
population increases, the need for more effective treatment is needed.
General conclusions-- MCAO experiments:
The results of the present study show that immunotherapy combined with
environmental enrichment does not significantly improve functional recovery nine weeks
after MCAO. Also, these treatments did not have a significant effect on dendritic
plasticity in layer V pyramidal neurons in the sensorimotor cortex. However, the total
branch segments showed a slight increase in the 11c7 Ab and control Ab groups
compared to the normal aged animals, but no difference was seen between the antibody
groups. Furthermore, our findings suggest that the anti-Nogo-A antibody did not have an
effect on the dendritic plasticity of the MCAO animals. Possibly the increase in dendritic
plasticity seen in the antibody groups could be attributed to the environmental enrichment
therapy. Perhaps environmental enrichment is acting to spare the dendrites after MCAO.
Compared to normal aged controls for total dendritic length, there is an overall slight
decrease in dendritic plasticity as compared to the normal aged control.
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Overall, the little difference seen in the animals who received the control antibody
was compared to the animals that received the Anti-Nogo-A antibody across all
experiments in this study. The results are not significant, probably due to the low number
of animals in each treatment group. Therefore, we cannot conclude that environmental
enrichment alongside immunotherapy does not lead to functional recovery or an increase
in dendritic plasticity in the aged rat after MCAO. With a larger group size, an increase
(or decrease) in both functional recovery and dendritic plasticity is a possible outcome in
future experiments. Also, a post lesion period beyond nine weeks, could provide more
significant results.
Nogo-A immunotherapy and MCAO:
Previous work from our lab showed that aged rats demonstrate recovery in the skilled
reaching task after 9 weeks. A significant difference was seen in the animals receiving
control antibody versus the anti-Nogo-A antibody (Markus et al., 2005). Parallels can be
drawn to previous work and the current experiments, but one must consider the
differences in the studies. The Markus study used Long Evans black-hooded rats (Markus
et al., 2005), while our study used Fisher 344 rats. It is possible that different rat strains
can lead to different results. This may be comparable to humans, whereby each elderly
stroke patient has a different pattern of stroke and recovery (Gillani et al., 2009). Also,
the previous study used the 7B12 anti-Nogo-A antibody (Markus et al., 2005) while we
used the 11c7 antibody. In contrast, the monoclonal 11c7 antibody is directed against
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amino acids 623-640 in the Nogo-A specific region in the rat. The monoclonal 7B12
antibody is specific for amino acids 760-820 in the Nogo-A specific region (Weinmann et
al., 2006). While both antibodies provide neutralizing effects to Nogo-A, they may act in
different ways. Both experimental methods demonstrate that functional recovery can be
found in aged animals with the use of immunotherapy, but this takes a long time. Further
experiments using different paradigms are needed to help promote functional recovery in
a shorter time period in aged rats.
Environmental enrichment and MCAO:
Other work in our lab examined environmental enrichment paired with amphetamine
as a treatment for recovery from MCAO (Papadopoulos et al., 2009). This previous study
used a similar environmental enrichment paradigm to that of the present study and found
that short-term treatment of amphetamine administration paired with environmental
enrichment led to marked improvement in forelimb reaching compared to control
animals. Although the experiments are quite similar to ours, some important differences
exist. One obvious and perhaps most important difference is the use of amphetamine
instead of immunotherapy. In several studies, amphetamine has been found to improve
functional recovery in the forelimb task after brain injury (Adkins & Jones, 2005;
Gilmour et al., 2005; Goldstein & Davis, 1990; Hovda & Fenney, 1984; Ramic et al.,
2006; Schmanke, Avery, & Barth, 1996; Stroemer & Rothwell, 1998). Moreover, this
previous work (Papadopoulos) used young adult Long-Evans black-hooded rats and the
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use of young animals in previous work represents another important difference. Taken
together, results suggest that environmental enrichment is a good form of therapy for the
aged population after brain injury, but more experiments will have to be done to achieve
a shorter recovery time in functional motor skill level.
Dendritic Plasticity and MCAO:
Previous work on the possible effect of Nogo-A neutralization on dendritic plasticity
in the adult rat after MCAO (Papadopoulos et al., 2006) found an increase in dendritic
complexity and spine density in layer V pyramidal neurons of the forelimb motor cortex
in the contralesional hemisphere. This finding is somewhat consistent with our current
experiments in that a slight, although statistically not significant, increase in the total
branch segments in our animals receiving MCAO. The previous work used a different
strain and age of rat (Long-Evans black-hooded; young adult), as well as a different
Nogo-A antibody (IN-1), and they did not employ environmental enrichment. Perhaps the
differences in age, strain of rat, lack of environmental enrichment, and antibody led to the
differences in results in the two groups. Again, the low numbers of animals in our
experimental studies, as well as their general fragility could have contributed to
dissimilar results. Overall, these experiments indicate that Nogo-A immunotherapy has
an effect on dendritic plasticity after MCAO in the rat.
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Stem cell therapy and MCAO:
In other work, human adult bone marrow-derived somatic cells (hABM-SCs) were
used to promote functional recovery after MCAO in the Long-Evans black-hooded
(Andrews et al., 2008). Specifically, animals with hABM-SCs treatment showed a
marked improvement in the forelimb reaching task one week after stroke. The
combination of stem cell therapy with immunotherapy or environmental enrichment may
prove to be interesting in future studies to determine if there is better functional recovery
in rats receiving MCAO. Moreover, it is deemed interesting to see whether stem cell
therapy improves functional performance in the aged rat model.
General Conclusions—TBI Experiments:
In recent TBI experiments animals showed improved functional recovery at four
weeks after stroke compared to the MCAO animals that took longer to recover. However,
no significant difference was found between the TBI animals receiving the control and
anti-Nogo-A antibody treatments. Analysis of dendritic plasticity in these animals
showed less branching, and the numbers were similar and slightly decreased as compared
to the normal aged animals. As for total dendritic length, an overall decrease in length
was found compared to the normal aged controls. Overall, the results show a decrease in
dendritic plasticity in the contralesional hemisphere compared to the normal aged animal.
No significant difference was seen in the two antibody groups for the TBI animals.
However, as noted with the MCAO experiments, the small group sizes des not enable
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statistical analysis. Therefore, only speculations may be made about how immunotherapy
may act on dendritic plasticity and functional recovery in the aged rat after TBI.
Comparison of MCAO and TBI Experiments:
Statistical significance was found when comparing animals recieving 11c7 Ab after
either MCAO or TBI in the Golgi analysis. A significant difference was seen in the two
groups (11c7 Ab/MCAO & 11c7 Ab/TBI) in total dendritic length (apical and basal), and
total branch segments (apical and basal). The MCAO group showed an increase in
dendritic plasticity in the contralesional hemisphere, while the TBI animals exhibited a
decrease in dendritic plasticity compared to the normal aged animals. Perhaps the
environmental enrichment combined with the anti-Nogo-A treatment spared dendrites in
the MCAO animals. Conclusions between the two studies are difficult because many
variables must be considered. An obvious example is the fact that MCAO and TBI are
two vastly different kinds of lesions that may have different effects on dendritic
plasticity, and also antibody treatment may differentially affect the two types of lesions.
Cortical lesions and rehabilitation:
Previous work in our lab showed that the combination of amphetamine treatment
with rehabilitation (focused activity and enriched housing) led to an enhancement in
neuronal plasticity which correlated with improved functional recovery after a cortical
lesion (Ramic et al., 2006). Important differences are to be seen between the current and
previous experiments. Perhaps the biggest difference is the treatment paradigms. In
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previous work with TBI, immunotherapy was used to promote rehabilitation in the
animals while amphetamine treatment was used in the other work (Ramic et al.). The
amphetamine experiments parallel Papadopoulos‟ (2008) experiments in the MCAO
model. Also a different strain of rat and age group was used. They also used the
sensorimotor cortical aspiration lesion model for their brain injury model, whereas our
lab used a controlled cortical impact injury (CCI) model. Combining the previous and
current work, we have proven that functional recovery can be seen in rats after a brain
lesion. An interesting experiment would be to compare amphetamine treatment versus
immunotherapy in the aged rat, as well as with and without environmental enrichment.
Much more work must be done to investigate how to achieve a shorter recovery time
after a cortical lesion.
Other work examined the affects of IN-1 immunotherapy after a cortical lesion on
corticostriatal plasticity (Kartje, Schulz, Lopez-Yunez, Schnell, & Schwab, 1999).
Animals treated with IN-1, as compared to control antibody promoted the sprouting in
corticostriatal projections to in the dorsolateral striatum contralateral to the injection site.
This study is comparable to recent work in that both cortical plasticity after traumatic
brain injury. However, the Kartje study used male and female adult Lewis Rats, whereas
we used aged male Fisher rats. The lesion model used for inducing the TBI was also
different, since the Kartje collaboration used a cortical aspiration lesion. Also, they used
the IN-1 antibody as compared to our use of 11c7 antibody. Even though there were
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differences seen between the two studies, they both proved that immunotherapy was
effective in promoting cortical plasticity.
Other work examined on the functional motor outcome in aged Nogo-A/B deficient
aged mice after traumatic brain injury (Marklund et al., 2009) demonstrated that such
mice showed poor performance on behavioral tasks, as well as an increase in white
matter loss in the brain. These results are contradictory studies using pharmaceutical
means to suppress Nogo-A. For example, Nogo suppression with IN-1 treatment
demonstrated functional recovery in animals with TBI. (Kartje 1999) Possibly, the
genetics of the Nogo-A/B deficient mice played a role in their overall brain development
and thus led to a more severe injury after TBI. (Marklund et al., 2009). Other than the
obvious difference in the way Markland‟s group and the way we blocked Nogo-A, the
animal species, age, and functional tasks were dissimilar in the two experimental
paradigms. The TBI model however was the same. Comparison of the two studies shows
that Nogo-A plays an important role in the functional recovery of animals after TBI.
Overall conclusions:
Overall, we have learned much from our experiments as well as the review of
studies done by other investigators. The major finding is that cortical injury in the aged
brain is very complex and many factors are to be considered. The effect of various
inhibitors in the brain that make it perhaps less plastic for repair must also be taken into
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account. The aged brain is especially susceptible to damage and is less capable of repair
in comparison to younger brains.
Our experimental design is considered interesting but, several things must change in
order to promote a more successful study. A larger group of animals is needed to improve
statistical analysis, although this is difficult in studies of aged, fragile animals. Possibly
more robust rat strains may be available for such work. On the other hand, perhaps the
Fisher rat is appropriate in resembling the fragile elderly human population. Use of the
appropriate animal model is perhaps one of the biggest problems in research. The large
variability in the human population represents an additional problem, as does the reduced
plasticity of the aged brain. However, numerous recent studies showing the adult brain to
be less rigid than previously thought does provide optimism. Additionally our
rehabilitative paradigm may have been too strenuous and tiring for the aged rats and thus
did not promote good health. On the other hand, rehabilitation may have been more
effective if started earlier than the four weeks after the animals received MCAO. Perhaps,
the physical therapy sessions should be introduced at the same time as the
immunotherapy to provide a more powerful challenge against the deficits of MCAO. The
introduction of physical rehabilitation examined the effect physical rehabilitation
combined with immunotherapy on animals with TBI may be a more beneficial.
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